1. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. https://doi.org/10.1183/13993003.00164-2019 https://pubmed.ncbi.nlm.nih.gov/30846476 
2. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659-68. https://doi.org/10.1016/S0140-6736(17)31281-3 https://pubmed.ncbi.nlm.nih.gov/28687413 
3. Macaluso C, Maritano Furcada J, Alzaher O, Chaube R, Chua F, Wells AU, et al. The potential impact of azithromycin in idiopathic pulmonary fibrosis. Eur Respir J. 2019;53(2):1800628. https://doi.org/10.1183/13993003.00628-2018 https://pubmed.ncbi.nlm.nih.gov/30442715 
4. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration. 2011;81(1):67-74. https://doi.org/10.1159/000320319 https://pubmed.ncbi.nlm.nih.gov/20733281 
5. Cirioni O, Ghiselli R, Silvestri C, Minardi D, Gabrielli E, Orlando F, et al. Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection. J Antimicrob Chemother. 2011;66(6):1318-23. https://doi.org/10.1093/jac/dkr107 https://pubmed.ncbi.nlm.nih.gov/21406436 
6. Black PN. Anti-inflammatory effects of macrolide antibiotics. Eur Respir J. 1997;10(5):971-2. https://doi.org/10.1183/09031936.97.10050971 https://pubmed.ncbi.nlm.nih.gov/9163632 
7. Simpson JL, Powell H, Baines KJ, Milne D, Coxson HO, Hansbro PM, et al. The Effect of Azithromycin in Adults with Stable Neutrophilic COPD: A Double Blind Randomised, Placebo Controlled Trial. In: PLoS One. 2014;9(8):e105609. https://doi.org/10.1371/journal.pone.0105609 https://pubmed.ncbi.nlm.nih.gov/25148049 
8. Asgrimsson V, Gudjonsson T, Gudmundsson GH, Baldursson O. Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob Agents Chemother. 2006;50(5):1805-12. https://doi.org/10.1128/AAC.50.5.1805-1812.2006 https://pubmed.ncbi.nlm.nih.gov/16641453 
9. Tojima I, Shimizu S, Ogawa T, Kouzaki H, Omura S, Sunazuka T, et al. Anti-inflammatory effects of a novel non-antibiotic macrolide, EM900, on mucus secretion of airway epithelium. Auris Nasus Larynx. 2015;42(4):332-6. https://doi.org/10.1016/j.anl.2015.02.003 https://pubmed.ncbi.nlm.nih.gov/25769240 
10. Suzuki T, Yamaya M, Sekizawa K, Hosoda M, Yamada N, Ishizuka S, et al. Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. Am J Respir Crit Care Med. 2002;165(8):1113-8. https://doi.org/10.1164/ajrccm.165.8.2103094 https://pubmed.ncbi.nlm.nih.gov/11956054 
11. Tan WC. Viruses in asthma exacerbations. Curr Opin Pulm Med. 2005;11(1):21-6. https://pubmed.ncbi.nlm.nih.gov/15591884 
12. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(9):1618-23. https://doi.org/10.1164/ajrccm.164.9.2105011 https://pubmed.ncbi.nlm.nih.gov/11719299 
13. Kobrehel G, Lazarevski G, Dokić S, Kolacny-Babić L, Kucisec-Iepes N, Cvrlje M. Synthesis and antibacterial activity of O-methylazithromycin derivatives. J Antibiot (Tokyo). 1992;45(4):527-34. https://doi.org/10.7164/antibiotics.45.527 https://pubmed.ncbi.nlm.nih.gov/1317368 
14. Stepanić V, Žiher D, Gabelica-Marković V, Jelić D, Nunhuck S, Valko K, et al. Physicochemical profile of macrolides and their comparison with small molecules. Eur J Med Chem. 2012;47(1):462-72. https://doi.org/10.1016/j.ejmech.2011.11.016 https://pubmed.ncbi.nlm.nih.gov/22152985 
15. Taylor SP, Sellers E, Taylor BT. Azithromycin for the prevention of COPD exacerbations: the good, bad, and ugly. Am J Med. 2015;128(12):1362.e1-6. https://doi.org/10.1016/j.amjmed.2015.07.032 https://pubmed.ncbi.nlm.nih.gov/26291905 
16. Kudoh S. Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med. 1998;4(2):116-21. https://doi.org/10.1097/00063198-199803000-00010 https://pubmed.ncbi.nlm.nih.gov/9612675 
17. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1829-32. https://doi.org/10.1164/ajrccm.157.6.9710075 https://pubmed.ncbi.nlm.nih.gov/9620913 
18. Castellani C, Duff AJ, Bell SC, Heijerman HG, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153-78. https://doi.org/10.1016/j.jcf.2018.02.006 https://pubmed.ncbi.nlm.nih.gov/29506920 
19. Amitani R, Wilson R, Rutman A, Read R, Ward C, Burnett D, et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol. 1991;4(1):26-32. https://doi.org/10.1165/ajrcmb/4.1.26 https://pubmed.ncbi.nlm.nih.gov/1898852 
20. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57(3):212-6. https://doi.org/10.1136/thorax.57.3.212 https://pubmed.ncbi.nlm.nih.gov/11867823 
21. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al.; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-56. https://doi.org/10.1001/jama.290.13.1749 https://pubmed.ncbi.nlm.nih.gov/14519709 
22. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax. 2006;61(10):895-902. https://doi.org/10.1136/thx.2005.057950 https://pubmed.ncbi.nlm.nih.gov/16809416 
23. Mayer-Hamblett N, Retsch-Bogart G, Kloster M, Accurso F, Rosenfeld M, Albers G, et al.; OPTIMIZE Study Group. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. Am J Respir Crit Care Med. 2018;198(9):1177-87. https://doi.org/10.1164/rccm.201802-0215OC https://pubmed.ncbi.nlm.nih.gov/29890086 
24. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, et al.; AZ0004 Azithromycin Study Group. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010;303(17):1707-15. https://doi.org/10.1001/jama.2010.563 https://pubmed.ncbi.nlm.nih.gov/20442386 
25. Mogayzel PJ, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al.; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-9. https://doi.org/10.1164/rccm.201207-1160OE https://pubmed.ncbi.nlm.nih.gov/23540878 
26. Olveira C, Padilla A, Martínez-García M-Á, de la Rosa D, Girón R-M, Vendrell M, et al. Etiology of Bronchiectasis in a Cohort of 2047 Patients. An Analysis of the Spanish Historical Bronchiectasis Registry. Arch Bronconeumol. 2017;53(7):366-74. https://doi.org/10.1016/j.arbres.2016.12.003 https://pubmed.ncbi.nlm.nih.gov/28118936 
27. Gao YH, Guan WJ, Liu SX, Wang L, Cui JJ, Chen RC, et al. Aetiology of bronchiectasis in adults: A systematic literature review. Respirology. 2016;21(8):1376-83. https://doi.org/10.1111/resp.12832 https://pubmed.ncbi.nlm.nih.gov/27321896 
28. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251-9. https://doi.org/10.1001/jama.2013.1937 https://pubmed.ncbi.nlm.nih.gov/23532241 
29. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660-7. https://doi.org/10.1016/S0140-6736(12)60953-2 https://pubmed.ncbi.nlm.nih.gov/22901887 
30. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309(12):1260-7. https://doi.org/10.1001/jama.2013.2290 https://pubmed.ncbi.nlm.nih.gov/23532242 
31. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. https://doi.org/10.1183/13993003.00629-2017 https://pubmed.ncbi.nlm.nih.gov/28889110 
32. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546-56. https://doi.org/10.1172/JCI36130 https://pubmed.ncbi.nlm.nih.gov/18982161 
33. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114-20. https://doi.org/10.1136/thorax.55.2.114 https://pubmed.ncbi.nlm.nih.gov/10639527 
34. Huckle AW, Fairclough LC, Todd I. Prophylactic Antibiotic Use in COPD and the Potential Anti-Inflammatory Activities of Antibiotics. Respir Care. 2018;63(5):609-19. https://doi.org/10.4187/respcare.05943 https://pubmed.ncbi.nlm.nih.gov/29463692 
35. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ, et al.; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-98. https://doi.org/10.1056/NEJMoa1104623 https://pubmed.ncbi.nlm.nih.gov/21864166 
36. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van’t Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361-8. https://doi.org/10.1016/S2213-2600(14)70019-0 https://pubmed.ncbi.nlm.nih.gov/24746000 
37. Pomares X, Montón C, Bullich M, Cuevas O, Oliva JC, Gallego M, et al. Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment. Chest. 2018;153(5):1125-33. https://doi.org/10.1016/j.chest.2018.01.044 https://pubmed.ncbi.nlm.nih.gov/29427576 
38. Naderi N, Assayag D, Mostafavi-Pour-Manshadi SM, Kaddaha Z, Joubert A, Ouellet I, et al. Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease. Respir Med. 2018;138:129-36. https://doi.org/10.1016/j.rmed.2018.03.035 https://pubmed.ncbi.nlm.nih.gov/29724384 
39. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218-24. https://doi.org/10.1164/rccm.200711-1754OC https://pubmed.ncbi.nlm.nih.gov/18480428 
40. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet. 1999;353(9171):2213-4. https://doi.org/10.1016/S0140-6736(99)01813-9 https://pubmed.ncbi.nlm.nih.gov/10392993 
41. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322-9. https://doi.org/10.1136/thoraxjnl-2012-202698 https://pubmed.ncbi.nlm.nih.gov/23291349 
42. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. [cited 2019 Aug 01]. Available from: http://www.ginaasthma.org/ 
43. Esteban-Gorgojo I, Antolín-Amérigo D, Domínguez-Ortega J, Quirce S. Non-eosinophilic asthma: current perspectives. J Asthma Allergy. 2018;11:267-81. https://doi.org/10.2147/JAA.S153097 https://pubmed.ncbi.nlm.nih.gov/30464537 
44. Gauthier JM, Hachem RR, Kreisel D. Update on Chronic Lung Allograft Dysfunction. Curr Transplant reports. 2016;3(3):185-91. https://doi.org/10.1007/s40472-016-0112-y https://pubmed.ncbi.nlm.nih.gov/28090432 
45. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003;168(1):121-5. https://doi.org/10.1164/rccm.200212-1424BC https://pubmed.ncbi.nlm.nih.gov/12672648 
46. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174(5):566-70. https://doi.org/10.1164/rccm.200601-071OC https://pubmed.ncbi.nlm.nih.gov/16741151 
47. Hansen MP, Scott AM, McCullough A, Thorning S, Aronson JK, Beller EM, et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. 2019;1:CD011825. https://doi.org/10.1002/14651858.CD011825.pub2 https://pubmed.ncbi.nlm.nih.gov/30656650 
48. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881-90. https://doi.org/10.1056/NEJMoa1003833 https://pubmed.ncbi.nlm.nih.gov/22591294 
49. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al.; ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352(16):1637-45. https://doi.org/10.1056/NEJMoa043526 https://pubmed.ncbi.nlm.nih.gov/15843666 
50. Bergman M, Huikko S, Huovinen P, Paakkari P, Seppälä H; Finnish Study Group for Antimicrobial Resistance (FiRe Network). Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006;50(11):3646-50. https://doi.org/10.1128/AAC.00234-06 https://pubmed.ncbi.nlm.nih.gov/16940064 
51. Cizman M. The use and resistance to antibiotics in the community. Int J Antimicrob Agents. 2003;21(4):297-307. https://doi.org/10.1016/S0924-8579(02)00394-1 https://pubmed.ncbi.nlm.nih.gov/12672574 
52. Čizman M, Bajec T, Korošec A. Poraba antibiotikov v Sloveniji in drugod po svetu. [cited 2019 Aug 22]. Available from: http://www.szpz.info/content/2018/podiplomskitecaj/Milan_Cizman_Tom_Bajec_Ales_Korosec-Poraba_antibiotikov_v_sloveniji_in_drugod.pdf 
53. Paragi M, Mioč V, Kastrin T, Kraigher A, Čretnik Žohar T. Slovenska skupina za meningitise. Invazivne pnevmokokne okužbe po uvedbi cepljenja s konjugiranim cepivom v nacionalni program cepljenja. Med Razgl. 2016;55:121-31. 
54.  . Pregled občutljivosti bakterij za antibiotike. Slovenija 2011. [cited 2019 Aug 22]. Available from: http://www.imi.si/strokovna-zdruzenja/skuopz/dokumenti/bakterijska-obcutljivost-v-sloveniji-2011.pdf 
55.  . Pregled občutljivosti bakterij za antibiotike. Slovenija 2017. [cited 2019 Aug 22]. Available from: http://www.imi.si/strokovna-zdruzenja/skuopz/dokumenti/skoupz_porocilo_2017_CIP.pdf 
56. Kastner U, Guggenbichler JP. Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. Infection. 2001;29(5):251-6. https://doi.org/10.1007/s15010-001-1072-3 https://pubmed.ncbi.nlm.nih.gov/11688901 
57. Taylor SL, Leong LEX, Mobegi FM, Choo JM, Wesselingh S, Yang IA, et al. Long-Term Azithromycin Reduces Haemophilus influenzae and Increases Antibiotic Resistance in Severe Asthma. Am J Respir Crit Care Med. 2019;200(3):309-17. https://doi.org/10.1164/rccm.201809-1739OC https://pubmed.ncbi.nlm.nih.gov/30875247 
58. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J. 2007;26(1):8-12. https://doi.org/10.1097/01.inf.0000247109.44249.ac https://pubmed.ncbi.nlm.nih.gov/17195698 
59. Tramper-Stranders GA, van der Ent CK, Gerritsen SA, Fleer A, Kimpen JL, Wolfs TF. Macrolide-resistant Staphylococcus aureus colonization in cystic fibrosis patients: is there transmission to household contacts? J Antimicrob Chemother. 2007;60(3):665-8. https://doi.org/10.1093/jac/dkm235 https://pubmed.ncbi.nlm.nih.gov/17604321 
60. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al.; Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34-42. https://doi.org/10.1136/gutjnl-2012-302254 https://pubmed.ncbi.nlm.nih.gov/22580412 
61. Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Forte A, Jeverica S. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol. 2016;28(6):676-83. https://doi.org/10.1097/MEG.0000000000000590 https://pubmed.ncbi.nlm.nih.gov/26862930 
62. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72:ii1-64. https://doi.org/10.1136/thoraxjnl-2017-210927 https://pubmed.ncbi.nlm.nih.gov/29054853 
63. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416. https://doi.org/10.1164/rccm.200604-571ST https://pubmed.ncbi.nlm.nih.gov/17277290 
64. Grosset J, Ji B. Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex. Drugs. 1997;54:23-7. https://doi.org/10.2165/00003495-199700542-00006 https://pubmed.ncbi.nlm.nih.gov/9358197 
65. Hosono Y, Kitada S, Yano Y, Mori M, Miki K, Miki M, et al. The association between erythromycin monotherapy for Mycobacterium avium complex lung disease and cross-resistance to clarithromycin: A retrospective case-series study. J Infect Chemother. 2018;24(5):353-7. https://doi.org/10.1016/j.jiac.2017.12.008 https://pubmed.ncbi.nlm.nih.gov/29361415 
